0001193805-24-000452.txt : 20240327
0001193805-24-000452.hdr.sgml : 20240327
20240327161532
ACCESSION NUMBER: 0001193805-24-000452
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240325
FILED AS OF DATE: 20240327
DATE AS OF CHANGE: 20240327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chivukula Pad
CENTRAL INDEX KEY: 0001727317
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38942
FILM NUMBER: 24790805
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcturus Therapeutics Holdings Inc.
CENTRAL INDEX KEY: 0001768224
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE
STREET 2: SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8589002660
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE
STREET 2: SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
e663461_4-chivukula.xml
X0508
4
2024-03-25
0
0001768224
Arcturus Therapeutics Holdings Inc.
ARCT
0001727317
Chivukula Pad
C/O ARCTURUS THERAPEUTICS HOLDINGS INC.
10628 SCIENCE CENTER DRIVE, SUITE 250
SAN DIEGO
CA
92121
0
1
0
0
Chief Scientific Officer & COO
1
Common Stock
2024-03-25
4
S
0
17435
35.0200
D
473448
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Reflects the weighted average price of 17,435 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 25, 2024, with sale prices ranging from $35.00 to $35.045 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
/s/ Ilan Katz, attorney-in-fact
2024-03-27